Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million
Wall Street Journal - WSJ TechMonday, May 19, 2025 at 11:48:00 AM
** Big pharma player Regeneron is swooping in to buy most of 23andMe’s assets for $256 million after the genetic testing company—once a buzzy darling of the direct-to-consumer health world—hit bankruptcy. The deal came together through a court-supervised auction, marking a quiet end for 23andMe’s independent run but giving its tech and data a lifeline under new ownership.
What This Means: ** Remember when everyone was spitting into tubes to learn about their ancestry and health risks? 23andMe rode that wave hard but eventually crashed. Now, Regeneron—a company more focused on drug development than consumer kits—gets its hands on a treasure trove of genetic data. For users, it’s a wait-and-see moment: Will their info fuel future medical breakthroughs, or just gather dust in a corporate vault? Either way, it’s a stark reminder of how volatile the consumer genetics gold rush turned out to be.
— Curated via WP Now’s AI editorial system
